Safety considerations in the pharmacological management of atrial fibrillation
- 21 July 2008
- journal article
- review article
- Published by Elsevier BV in International Journal of Cardiology
- Vol. 127 (3), 299-306
- https://doi.org/10.1016/j.ijcard.2007.11.006
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- AFFIRM and RACE Trials: Implications for the Management of Atrial FibrillationCardiac Electrophysiology Review, 2003
- A Risk Score for Predicting Stroke or Death in Individuals With New-Onset Atrial Fibrillation in the CommunityJAMA, 2003
- Atrial Fibrillation Is Associated with Severe Acute Ischemic StrokeNeuroepidemiology, 2003
- Atrial fibrillation: epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm.Journal of Cardiovascular Pharmacology and Therapeutics, 2003
- A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial FibrillationNew England Journal of Medicine, 2002
- A Comparison of Rate Control and Rhythm Control in Patients with Atrial FibrillationNew England Journal of Medicine, 2002
- Increased Atrial Fibrillation Mortality: United States, 1980-1998American Journal of Epidemiology, 2002
- Prevalence of Diagnosed Atrial Fibrillation in AdultsJAMA, 2001
- Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trialThe Lancet, 2000
- Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implicationsArchives of Internal Medicine, 1995